Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pathological Processes in the Posterior Fossa
Conditions
Pathological Processes in the Posterior Fossa, Dura Defects
Trial Timeline
May 1, 2008 → Mar 1, 2010
NCT ID
NCT00681824About Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) is a phase 2 stage product being developed by Baxter for Pathological Processes in the Posterior Fossa. The current trial status is completed. This product is registered under clinical trial identifier NCT00681824. Target conditions include Pathological Processes in the Posterior Fossa, Dura Defects.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00892957 | Phase 3 | Completed |
| NCT00681824 | Phase 2 | Completed |
Competing Products
4 competing products in Pathological Processes in the Posterior Fossa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olanzapine + sugar pill | Eli Lilly | Phase 3 | 77 |
| Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT | Novartis | Phase 3 | 77 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Gadoversetamide | Guerbet | Approved | 77 |